Accès ouvert déclaré 2024 article

The impact of pulmonary embolism on health outcomes of COVID-19 at 3 months after hospitalization

Chantal Visser, Julia C. Berentschot, Cindy M.M. de Jong, M. Louisa Antoni, L. Martine Bek, Rita J. G. van den Berg-Emons, Bram van den Borst, Hugo Ten Cate, Arina J. ten Cate‐Hoek, Dionne C.W. Braeken, J.J. Miranda Geelhoed, Majanka H. Heijenbrok‐Kal, Sander M. J. van Kuijk, Lucia J.M. Kroft, Jenneke Leentjens, Anna H.E. Roukens, Suzanne C. Cannegieter, Frederikus Albertus Klok, Marieke J.H.A. Kruip, Merel E. Hellemons

1Citations signalées, ce qui n’est pas une note de qualité

8Institutions déclarées

1Pays d’affiliation déclarés

Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Background: COVID-19 patients frequently experience pulmonary embolism (PE), but its long-term consequences remain uncertain. Objectives: To assess the impact of PE in COVID-19 patients on health outcomes at 3 months after hospitalization. Methods: In this multicenter cross-sectional study, we aggregated data from existing databases to evaluate the impact of PE on health outcomes at 3 months after hospitalization. We assessed 1) questionnaires on health-related quality of life (5-level EuroQol 5-dimensional questionnaire [EQ-5D-5L] questionnaire), anxiety, depression, cognitive failure, and posttraumatic stress disorder; 2) pulmonary function tests (diffusing capacity of the lungs for carbon monoxide [DLCO] and spirometry); and 3) radiological abnormalities. We developed 3 models to assess the association between PE and the EQ-5D-5L index and the percentage of predicted DLCO (DLCO%): a crude model (model 1), adjusted for age, sex, and presence of comorbidities (model 2), and model 2 additionally adjusted for intensive care unit admission (model 3). Results: We included 465 patients who had been hospitalized for COVID-19, of whom 102 (21.9%) had developed a PE during admission. Patients with PE had poorer EQ-5D-5L index values, more impairment in pulmonary functions, and more frequent radiological abnormalities than patients without PE. Symptoms of anxiety, depression, cognitive failure, and posttraumatic stress disorder did not differ between the 2 groups. In model 2, PE was associated with lower EQ-5D-5L index and lower DLCO%. After additionally adjusting for intensive care unit admission, the association between PE and lower EQ-5D-5L index (mean difference = -0.069, [95% CI, -0.12 to -0.017]) remained but not between PE and DLCO%. Conclusion: Our findings suggest that PE in COVID-19 patients is associated with reduced health-related quality of life at 3 months after hospitalization. While PE may be a marker of COVID-19 severity, its presence during hospitalization could indicate potential long-term health issues, which may be considered during follow-up care.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: The impact of pulmonary embolism on health outcomes of COVID-19 at 3 months after hospitalization
Date Crossref: 01/10/2024
Éditeur: Elsevier BV
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Erasmus MC pays non établi dans la notice
Établissement de santé
Erasmus University Rotterdam pays non établi dans la notice
Université ou école supérieure
Leiden University Medical Center Department of Medicine - Thrombosis and Hemostasis pays non établi dans la notice
Organisme public
Radboud University Nijmegen pays non établi dans la notice
Université ou école supérieure
Radboud University Medical Center Department of Pulmonary Diseases pays non établi dans la notice
Organisme public
Maastricht University Medical Centre Department of Biochemistry pays non établi dans la notice
Organisme public
Maastricht University Department of Internal Medicine pays non établi dans la notice
Université ou école supérieure
Radboud Institute for Molecular Life Sciences pays non établi dans la notice
Structure de recherche
Erasmus University Medical Center Rotterdam Department of Hematology pays non établi dans la notice
Université ou école supérieure
Cardiovascular Research Institute Maastricht (CARIM) pays non établi dans la notice
Structure de recherche

Erasmus MC, Erasmus University Rotterdam et Department of Medicine - Thrombosis and Hemostasis — Leiden University Medical Center, avec 7 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Venous Thromboembolism Diagnosis and ManagementCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI